Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
← catalyst calendarNCT07098806 · readout in 43 d
Sponsored by Plus Therapeutics (industry) · PSTV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
24estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-02 | actual | When the study began enrolling |
| Primary completion | 2026-10-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-10-02 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Leptomeningeal Metastasis
Intervention
- Drug: 186RNL
Primary outcomes
what the primary-completion date above is the date OFMaximum Tolerated Dose
measured 13 months
Dose Distribution of 186RNL
measured 13 months
Safety and tolerability of multiple dose treatment
measured 13 months
Permalink · PSTV's whole pipeline · Catalyst calendar · Every registered study · What changed